Welcome to our dedicated page for EMMAUS LIFE SCIENCES news (Ticker: EMMA), a resource for investors and traders seeking the latest updates and insights on EMMAUS LIFE SCIENCES stock.
Emmaus Life Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for rare and orphan diseases. Their primary product development is centered around sickle cell disease, a genetic disorder. Their leading product candidate, an oral pharmaceutical grade L-glutamine treatment, has demonstrated positive results in phase 3 clinical trials for sickle cell anemia and sickle ß0-thalassemia. Emmaus Life Sciences is committed to improving the lives of patients with sickle cell disease worldwide.
Emmaus Life Sciences, Inc. (OTCQX: EMMA) announced its Q2 2022 financial results, reporting net revenues of $4.3 million, down from $6.5 million in Q2 2021. The company experienced a 33% increase in Q2 revenues from Q1 2022, driven by sales of Endari in the U.A.E. Net loss for Q2 2022 totaled $8.9 million or $0.18 per share, compared to a net income of $2.5 million in Q2 2021. Operating expenses decreased slightly to $5.3 million. The company reported cash and cash equivalents of $1.0 million as of June 30, 2022, and is exploring debt restructuring.
Emmaus Life Sciences, Inc. (OTCQX: EMMA) has engaged Acorn Management Partners to enhance investor awareness among financial professionals. This collaboration aims to broaden Emmaus's investor base in the U.S. and the Middle East North Africa region. Emmaus, a leader in sickle cell disease treatment, markets the FDA-approved Endari® (L-glutamine oral powder). Acorn’s expertise in investor relations and their strategic outreach program will support Emmaus's goal to deliver its innovative therapies effectively.
Emmaus Life Sciences, Inc. (OTCQX: EMMA), based in Torrance, California, will participate in two investor conferences in May 2022. The first event, the Q2 Investor Summit, will occur on May 3-4, where CEO Yutaka Niihara will present at 3:30 p.m. ET. The H.C Wainwright Global Investment Conference is scheduled for May 23-26, with an on-demand presentation available from May 24, 2022, at 7:00 a.m. ET. One-on-one meetings can be arranged with management during both conferences.
Emmaus Life Sciences (OTQXC: EMMA) has launched a full-service telehealth solution to enhance access to its product Endari®, an L-glutamine oral powder for sickle cell disease treatment. This initiative, in partnership with Asembia LLC, US Bioservices Corporation, and UpScript IP Holdings, enables patients to receive prescriptions and home delivery, improving patient experience and adherence rates. With the telehealth market experiencing significant growth, Emmaus aims to reach new patients and generate revenue through this innovative service.
Emmaus Life Sciences (OTCQX: EMMA) reported significant findings from a study on Endari®, an oral L-glutamine powder, in treating sickle cell disease. Conducted in French Guiana and Qatar, the observational study showed that patients had fewer vaso-occlusive crises and hospitalizations over 72 weeks compared to baseline, with statistically significant reductions in blood transfusions and improved hemoglobin levels. The study, presented at the 62nd Annual Meeting of the British Society for Haematology, reinforces the effectiveness of Endari in enhancing patient outcomes for sickle cell disease.
Emmaus Life Sciences announced that Florida has approved the inclusion of Endari, its prescription-grade L-glutamine oral powder, on the Medicaid Preferred Drug List (PDL) starting April 1, 2022. This decision means Endari can be prescribed without prior authorization, streamlining access for patients suffering from sickle cell disease. Florida joins several other states in eliminating prior authorization for this medication. CEO Yutaka Niihara emphasized that this approval brings them closer to making Endari widely available to healthcare providers.
On March 23, 2022, Emmaus Life Sciences announced the U.A.E. Ministry of Health approved its marketing application for Endari®, a treatment for sickle cell disease. After a five-month review, Endari was previously available only on an early access basis. Emmaus estimates about 600 sickle cell patients reside in the U.A.E. and approximately 225,000 in the MENA region could benefit from the drug. The company aims to secure further approvals across Gulf Cooperation Council states, highlighting the significance of this market due to the higher prevalence of sickle cell disease compared to the U.S.
Emmaus Life Sciences (OTCQX: EMMA) announced that Yutaka Niihara, CEO, will present a company overview at the H.C. Wainwright BioConnect Conference from January 10-13, 2021. The presentation will be available on-demand starting at 7:00 a.m. Eastern Time on January 10, and can be accessed on Emmaus' website. Emmaus Life Sciences is a leader in treating sickle cell disease and markets the FDA-approved Endari® (L-glutamine powder) for reducing complications related to this condition.
Emmaus Life Sciences (OTCQX: EMMA) announced positive transfusion data from a post-hoc analysis of its phase 3 clinical study of Endari, an L-glutamine oral powder for sickle cell disease (SCD). Presented at the 63rd ASH Annual Meeting, the study showed that patients on Endari required approximately 43% fewer units of red blood cells compared to those on placebo over 48 weeks. The multicenter trial included 230 patients, indicating that Endari significantly reduces pain crises and hospitalizations. This highlights its potential as a complementary therapy alongside hydroxyurea.
Emmaus Life Sciences (OTCQX: EMMA) announced that its CEO, Yutaka Niihara, will present live on VirtualInvestorConferences.com on December 16 at 12:30 PM ET. Investors can engage with the company during this interactive online event, which will also be archived for later viewing. Attendees are encouraged to pre-register and check their systems for a smooth experience. Emmaus Life Sciences specializes in treating sickle cell disease and markets FDA-approved Endari, aimed at reducing acute complications of the condition.
FAQ
What is the current stock price of EMMAUS LIFE SCIENCES (EMMA)?
What is the market cap of EMMAUS LIFE SCIENCES (EMMA)?
What is the focus of Emmaus Life Sciences, Inc.?
What is the main product development focus of Emmaus Life Sciences, Inc.?
What has Emmaus Life Sciences, Inc.'s lead product candidate shown in clinical trials?
In what geographical region has Emmaus Life Sciences, Inc. received marketing authorization for their product?
Where else is Endari® approved for marketing?
What is the indication for Endari®?
What is the safety information related to Endari®?
What are the common symptoms of sickle cell disease?
What is Emmaus Life Sciences, Inc.'s mission?
What are the key achievements of Emmaus Life Sciences, Inc.?
